Business
Extension of Warrants in Incanthera to 31 Mar 2025
Extension of Warrants in Incanthera to 31 Mar 2025.
About this update from Immupharma Plc
[{"type":"text","content":"\n\n \n 9 September 2024\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nExtension of Warrants in Incanthera to 31 March 2025\n \nImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (\"Incanthera\") that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera's IPO onto the Aquis Exchange, are extended by a further period to 31 March 2025.\n \nKey highlights:\n \n· The Company entered into a Warrant Instrument (\"Warrant Instrument\") with Incanthera on 26 February 2020, whereby Incanthera created and issued Warrants to ImmuPharma to subscribe in cash at 9.5p per share, for 7,272,740 Ordinary Shares, valid until 6 September 2023. On 18 August 2023 Incanthera agreed with the Company to extend the Warrant Instrument by 12 months to 6 September 2024.\n \n· Incanthera has now agreed with the Company to extend the Warrant Instrument to 31 March 2025.\n \n· A cash consideration of £75,000 (\"Consideration\") has been paid by ImmuPharma to obtain the extension.\n \n· Other than the change in the expiry period, all other provisions in the Warrant Instrument remain the same.\nImmuPharma currently owns no shares in Incanthera, having sold ...